Skip to contentL
Lexicon Pharmaceuticals, Inc.
L
LXRXLexicon Pharmaceuticals, Inc. Q2 2014 · 10-Q
Revenue$376.00K$376.00K−44.4% vs Q2 2013 Net Income-$28.07M-$28.07MN/M vs Q2 2013 EPS Diluted-$0.27-$0.27N/M vs Q2 2013 Operating Income-$26,688,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Lexicon Pharmaceuticals, Inc. · CIK 1062822 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$32,641,000N/M Margins · derivedOperating margin-7097.9%−3235.3 pt vs Q2 2013
Net margin-7466.5%−3616.2 pt vs Q2 2013
ended Jun 30, 2015 · filed Aug 7, 2015 · 38 d after period end